Related Experiment Video

Updated: Apr 26, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

2.7K

The PML domain of PML-RARα blocks senescence to promote leukemia

Katharina Korf1, Harald Wodrich2, Alexander Haschke1

  • 1Research Institute Children's Cancer Center Hamburg, 20251 Hamburg, Germany;

Proceedings of the National Academy of Sciences of the United States of America
|August 6, 2014
PubMed

Insights

Mouse PML-RARα fusion protein is more effective at causing leukemia than human PML-RARα. This enhanced leukemogenic oncoprotein prevents cellular senescence by impeding cell-cycle regulators, offering a potential therapeutic target for acute promyelocytic leukemia.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute promyelocytic leukemia (APL) is often caused by PML-RARα fusion genes.
  • The human PML fusion promotes leukemia in mice, but with low efficiency.

Purpose of the Study:

  • To investigate the leukemogenic potential of murine PML-RARα (mPR) compared to its human counterpart.
  • To elucidate the mechanisms by which mPR induces leukemia, focusing on cellular senescence.

Main Methods:

  • Generation of a murine PML-RARα (mPR) hybrid protein.
  • Assessment of mPR's leukemogenic potential in mice.
  • Analysis of cell-cycle regulators (p21, p19ARF) and senescence pathways.
  • Investigation of the ATRX/Daxx-histone H3.3 complex in mPR-induced leukemia.

Main Results:

  • The murine PML-RARα (mPR) protein is significantly more leukemogenic than the human PML fusion.
  • mPR promotes cellular immortalization by inhibiting senescence.
  • This inhibition is linked to impeded up-regulation of p21 and p19(ARF) cell-cycle regulators.
  • mPR induction of leukemia involves a loss of the ATRX/Daxx-histone H3.3 complex.

Conclusions:

  • Murine PML-RARα is a more potent leukemogenic oncoprotein than human PML-RARα.
  • Inhibition of cellular senescence is a key mechanism in mPR-driven leukemia.
  • Targeting senescence pathways may offer a novel therapeutic strategy for APL.
Keywords:
PML nuclear bodieshematopoiesishistone chaperonesleukemogenesisoncogenes

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

22.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

4.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K